Health Condition 1: N202- Calculus of kidney with calculus of ureter
Conditions
Interventions
Intervention1: Silodosin group: Silodosin 8 mg oral capsule, administered once daily for 5 consecutive days prior to the scheduled retrograde intrarenal surgery (RIRS).
Control Intervention1: Placebo
Sponsors
Dr Mathi Sri Akshay
Eligibility
Inclusion criteria
Inclusion criteria: Patients with renal calculi less than2 cm planned for primary retrograde intrarenal surgery (RIRS) Normal renal function Patients able and willing to provide written informed consent ASA (American Society of Anesthesiologists) Grade I III
Exclusion criteria
Exclusion criteria: Pregnant or lactating women Patients with solitary kidney or anatomical abnormalities (PUJO, ureteric stricture, horseshoe kidney) Previous ureteric surgery or stenting on the side of surgery Known allergy or contraindication to alpha-blockers Patients already on alpha-blocker therapy for other indications Severe hepatic, renal, or cardiovascular disease (ASA grade IV) Active urinary tract infection or fever at presentation Patients unwilling or unable to comply with study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Successful access sheath placement without the need for active ureteric dilatationTimepoint: Intraoperative, assessed at the time of ureteric access sheath placement during the RIRS procedure. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of ureteric injury Mean operative time Stone-free rate (no residual fragments less than two mm on CT KUB) Adverse drug reactions attributable to silodosin ( dizziness, postural hypotension, retrograde ejaculation)Timepoint: Operative time and ureteric injuries during surgery, intra operative. Stone free rate two weeks post surgery | — |
Countries
India
Contacts
Public ContactDr Mathi Sri Akshay
Department of Urology, Government Mohan Kumaramangalam Medical College Hospital Salem
Outcome results
None listed